ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Volume: 35, Issue: 3, Pages: 401
Published: Mar 18, 2019
Abstract
Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease, but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially CRPC remains dependent on androgen receptor (AR) signaling, often through increased expression of full-length AR (ARfl) or expression of dominantly active splice variants such as ARv7. We show in ARv7-dependent CRPC models that ARv7 binds together with ARfl to...
Paper Details
Title
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
Published Date
Mar 18, 2019
Volume
35
Issue
3
Pages
401
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.